a244d11 gp120
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2023 (NCT05769569)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06484335 | Phase 1 | Feb 1, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 2 | 2 | 1 | 2023 |
| United States Army | Government | 2 | 0 | 1 | 2023 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1